

Drug Misuse Prevention Committee meeting

Date: 28/1/16

Location: NICE London office, Derwent Room
10 Spring Gardens, London, SW1A 2BU

Minutes: Final

Committee members present:		
David Croisdale-Appleby (Chair)		(Present for notes 1 – 13)
Janis Baird (Core)		(Present for notes 1 – 13)
Ross Cowan (Community Core)		(Present for notes 1 – 13)
Hiten Dodhia (Core)		(Present for notes 1 – 13)
Rose Durban (Core)		(Present for notes 1 – 13)
Eileen Kaner (Core)		(Present for notes 5 – 13)
Stephen Morris (Core)		(Present for notes 1 – 13)
Kamran Siddiqi (Core)		(Present for notes 3 – 13)
Jasmine Murphy (Core)		(Present for notes 1 – 13)
Blaine Stothard (Topic Expert)		(Present for notes 1 – 13)
April Wareham (Community Topic Expert)		(Present for notes 1 – 13)

In attendance:		
Adrienne Cullum	Technical Lead, NICE	(Present for items 1 – 13)
Ella Novakovic	Senior Technical Analyst, NICE	(Present for items 1 – 13)
Alastair Fischer	Health Economist, NICE	(Present for items 1 – 13)
Thomas Hudson	Information Specialist, NICE	(Present for items 1 – 13)
Ian Wall	Assistant Project Manager, NICE	(Present for items 1 – 13)
Brendan Collins	Liverpool University	(Present for items 6 – 13)
Peter Burkinshaw	Expert testimony:	(Present for item 10)

PHAC C minutes 28th January 2016

	Public Health England	
Jim McVeigh	Expert testimony: Liverpool John Moores University	(Present for item 11)

Observers:	
Alice Murray	(Present for items 4 – 13)
Aedin McSloy	(Present for items 3 – 12)
Rosa Domingues	(Present for items 1 – 13)
Stephanie Fernley	(Present for items 1 – 13)

Apologies:	
Paul McArdle	Topic Expert
Jim McCambridge	Topic Expert
Rachel Bundock	Topic Expert

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the third meeting on Drug Misuse Prevention. The Committee members and attendees introduced themselves.

The Chair welcomed a member of the public to the meeting. The member of the public had been briefed already, both verbally and in writing by the NICE team, and the Chair reminded them of the protocol for members of the public, whose role is to observe (they should not speak or ask questions). No filming or recording of the meeting is permitted. The Chair reminded all present that the Committee is independent and advisory, that its decisions and recommendations to NICE do not represent final NICE guidance, and that they may be changed as a result of public consultation.

The Chair informed the Committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting, which included:

- Discussing updated evidence review 1
- Discussing evidence review 2

- Discussing the economic modelling
- Hearing expert testimony
- Drafting recommendations, committee discussion and research recommendation

2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was in relation to ‘Drug misuse prevention: targeted interventions’.

The Chair asked everyone to verbally declare any interests that they have in regard to the matter under discussion.

Name	Job title, organisation	Declarations of Interest, date declared	Decision taken
Janis Baird	Associate Professor of Public Health Medicine, MRC Lifecourse Epidemiology Unit	I and a group of colleagues at the MRC Lifecourse Epidemiology Unit, University of Southampton, have received funding from Danone Nutrica Early Life Nutrition for a specific research study which aims to improve the nutrition and Vitamin D status of pregnant women. <i>(25/6/15 on recruitment)</i>	
		I am a member of the NIHR Research for Patient Benefit South Central Advisory Committee <i>(17/12/15 at PHAC C meeting)</i>	
Rachel Bundock	Young People’s Director, Compass	Executive Director - Compass (Voluntary sector organisation) that competitively bids to provide a range of drug prevention, early intervention, targeted and specialist substance misuse and risk taking behaviour services for children and young people across a number of local authorities. <i>(2/11/15 pre PHAC 1)</i>	
Ross Cowan	Community core member	Unpaid Trustee of the Health and Race Equality Forum (HAREF), a small charity based in Newcastle which receives funding to carry out involvement and engagement activities around health and related	

PHAC C minutes 28th January 2016

		issues.	
		Health and Wellbeing Policy Associate with Voluntary Organisations Network North East which receives funding from, and is a part of, Regional Voices, one of 21 voluntary sector networks and organisations in the DH, NHS England and Public Health England Strategic Partners Programme.	
David Croisdale-Appleby	Professor/Executive Chair, Standing Commission on Carers	<p>Chair of Skills for Care 2008 – 2014</p> <p>Chair of Skills for Care and Development 2008 – 2014</p> <p>Chair of Hft 2010 – 2015</p> <p>Executive Chair of the Standing Commission on Carers 2014 – present</p> <p>Chair of Dementia UK 2013 – present</p> <p>Board Member of Health Education England 2014 - present</p> <p>Board Member of Think Ahead 2014 – present</p> <p>Member, Cross-Government Council on the New Carers Strategy 2015 – present</p> <p>Professor at the School of Medicine and Health, Durham University</p> <p>Professor at the Wolfson Research Institute for Health and Wellbeing</p> <p>Professor at the Durham University Business School</p> <p>Visitor/Inspector of Medical Education, General Medical Council 2001 – present</p> <p><i>(3/4/15 before PHAC)</i></p>	
Hiten Dodhia	Assistant Director Health Intelligence &	<p>None</p> <p><i>(22/6/15 on recruitment)</i></p>	

PHAC C minutes 28th January 2016

	Analysis/Consultant in Public Health, Southwark Council		
Rose Durban	Director, RGC Consulting Ltd	Through my company, RGC Consulting Ltd, I undertake some part-time work as an adviser for the DfE (Department for Education) providing children's social care advice, support and challenge to those local authorities in intervention following adverse Ofsted inspection judgement on their Children's Services arrangements. <i>(29/10/15 pre PHAC 1)</i>	
Eileen Kaner	Professor of Public Health Research, Newcastle University	I am a Professor of Public Health and Primary Care Research at Newcastle University and have formed conclusions, derived from evidence, on primarily alcohol and public health issues. I have also previously chaired a NICE PDG (PH24) focused on alcohol and prevention. The work of my current PHAC has not covered these areas of my expertise. Hence I believe I have no non-pecuniary personal or professional conflicts to declare. <i>(4/9/15 from annual declaration)</i>	
		I am a member of the NIHR Public Health funding board.	
		I also have a number of funded studies that focus on alcohol and substance use in several of the groups focussed on including looked after children, people in criminal justice systems, people with mental health & substance use problems.	
		I also have an alcohol research UK PhD studentship on family involved interventions for young people with substance use and mental health problems <i>(17/12/15 from PHAC C meeting)</i>	

PHAC C minutes 28th January 2016

Paul McArdle	Consultant Child and Adolescent Psychiatrist, Northumberland Tyne and Wear NHS Foundation Trust	None <i>(29/4/15 on recruitment)</i>	
Jim McCambri dge	Prof, Addictive Behaviours & Public Health, University of York	I have recently been awarded a research grant by NIHR-PHR to do a systematic review of novel psychoactive substances <i>(29/4/15 on recruitment)</i>	
		I have co-authored papers that may be considered as part of the evidence review for this guideline.	
Stephen Morris	Professor of Health Economics, University College London	From October 2014 to June 2015 I received consultancy fees from Health Education North Central and East London to undertake a scoping project to evaluate the future need for Speech and Language Therapists in London.	
		From January 2015 to July 2015 I received consultancy fees from social enterprise Oomph Wellness to undertake a pilot study to evaluate the cost-effectiveness of the Oomph! programme, which provides exercise and activity classes for older people in care homes.	
		From September 2011 to September 2012 I received consultancy fees from GlaxoSmithKline to undertake a cost-effectiveness analysis of mepolizumab in adults and adolescents with severe asthma.	
		From September 2011 to the present I have been a member of the NIHR Public Health Research Programme Research Funding Board.	
		From October 2014 to the present I have been a member of the NIHR Health Services and Delivery Research Programme Funding Board.	

PHAC C minutes 28th January 2016

		From April 2015 to the present I have been a member of the NIHR Programme Grants for Applied Research expert sub-panel.	
Jasmine Murphy	Consultant in Public Health, Leicester City Council	None <i>(1/9/15 from annual declaration)</i>	
Kamran Siddiqi	Clinical Senior Lecturer, University of York	On behalf of my institution (University of York), I have received research funding from MRC, NIHR, CRUK (a cancer charity involved in advocacy for cancer patients), and IDRC (International Development Research Centre in Canada). <i>(7/9/15 from annual declaration)</i>	
		I work at the Institute of Health Sciences at University of York that has an interest in a number of public health areas of research and have secured research grants from NIHR, MRC and several other organizations for a variety of public health topics <i>(7/9/15 from annual declaration)</i>	
		I have a personal academic interest in a number of public health research topics including tobacco cessation, second-hand smoking, preventing tobacco uptake and ethnicity and health. I have written and presented on these topics <i>(7/9/15 from annual declaration)</i>	
Blaine Stothard	Prevention Specialist, Blaine Stothard Consultancy	I have written journal articles and authored and co-authored book chapters on drug policy and drug prevention. I have contributed to teaching resources on drug education. I am co-editor of the journal Drugs and Alcohol Today. <i>(26/10/15 pre PHAC 1)</i>	
April Wareham	Community topic expert member	As an independent consultant trainer I have been paid by Martindale Pharma to deliver training to drug and alcohol professionals/prisons	

	<p>staff/policy/social workers etc. in the use of Prenoxad (naloxone hydrochloride 1mg/1ml). September 2014 to date</p> <p><i>(14/8/15 from Annual Declaration)</i></p>	
	<p>Director of Working with Everyone: we were contracted on a consultancy basis by Martindale Pharma to deliver a number of training sessions to Boots pre-reg pharmacists. February 2015</p>	
	<p>Director SMMGP: the organisation receives sponsorship for its Annual Conference from a number of organisations, including pharmaceutical companies. The organisation has received education grants from various pharmaceutical companies. Ongoing</p> <p><i>(14/8/15 from Annual Declaration)</i></p>	

The contractor present at the meeting (Brendan Collins, University of Liverpool) was also asked to make any declarations of interest.

The Chair and a senior member of the Developer's team noted that the interests declared did not prevent the attendees from fully participating in the meeting.

3. Minutes of last meeting

The Chair asked the Committee if it wanted any changes made to the minutes of the last meeting.

The Committee agreed that the minutes were a true and accurate account of the meeting otherwise.

The Chair confirmed that all matters arising had been completed or were in hand. Members were thanked for all their written comments and information submitted (following actions from the last meeting).

4. Evidence review 1 (updated)

The Chair introduced Ella Novakovic, Senior Technical Analyst at NICE, who gave an overview of the updated evidence review plan on drugs misuse prevention.

The Committee discussed the updated evidence statements in relation to the

guideline and were given the opportunity to ask questions.

Action: NICE to further update evidence statements in light of committee comments and circulate to the committee for comment by Monday 8th February.

Action: NICE to undertaken consistency check across evidence tables, narrative and statements

The Chair thanked Ella for her presentation.

5. Evidence review 2

The Chair introduced Ella Novakovic, Senior Technical Analyst at NICE, who gave an overview of the evidence review 2 findings for groups 1 to 9 on drugs misuse prevention.

The Committee discussed the evidence statements in relation to the guideline and were given the opportunity to ask questions.

Action: NICE to update the review and evidence statements in light of committee comments and circulate to the committee with papers for the next meeting.

Action: NICE to undertaken consistency check across evidence tables, narrative and statements

The Chair thanked Ella for her presentation.

6. Options for economic modelling including sources of data

The Chair introduced Brendan Collins, Research Fellow in Health Economics at Liverpool University, who gave a presentation on the updated options for economic modelling including sources of data.

The Committee discussed modelling options in relation to the guideline and were given the opportunity to ask questions.

Action: Members asked to forward to the NICE team any additional information that might address data gaps for the economic modelling.

The Chair thanked Brendan for his presentation.

7. Expert testimony: current provision and future issues for commissioning

The Chair introduced Peter Burkinshaw, Alcohol, drug treatment and recovery lead in the Alcohol, Drug and Tobacco Division in Public Health England who gave a

presentation on current provision and future issues for commissioning.

The Committee were given the opportunity to ask questions.

Action: NICE to circulate presentation

Action: Members to forward additional questions from committee for PHE, for consideration as part of the written testimony.

Action: NICE to circulate received expert testimony paper

The Chair thanked Peter for his presentation.

8. Expert testimony: performance and image enhancing drugs

The Chair introduced Jim McVeigh, Director of the Centre for Public Health and Reader in Substance Use Epidemiology at Liverpool John Moores University, who gave a presentation on performance and image enhancing drugs.

The Committee were given the opportunity to ask questions.

Action: NICE to circulate presentation

Action: Members to forward additional questions from committee for Jim McVeigh, for consideration as part of the written testimony.

Action: NICE to circulate received expert testimony paper

The Chair thanked Jim for his presentation.

9. Drafting guideline recommendations and research recommendations

The Committee drafted guideline recommendations and research recommendations based on the evidence presented.

Action: NICE to further draft recommendations, research recommendations and committee discussion based on comments received.

Action: NICE to circulate PH4 with papers for next meeting.

10. Summary of the day and next steps, including suggestions for expert testimony

The Chair summarised the discussion from the day and highlighted that the next meeting on this topic would take place on 3rd March 2016.

Action: The Committee to suggest any additional topic experts who may be able to provide the NICE review team with further knowledge in order to

PHAC C minutes 28th January 2016

address any gaps in the evidence

The Committee agreed to receive papers for the third committee meeting 5 days in advance of the meeting.

All committee members were reminded that expenses must be submitted within 3 months of a meeting taking place.

11. Any other business

Noted that this was the last meeting for NICE health economist Alastair Fischer who is leaving NICE in February. Alastair was thanked for all his input to the work of the committee.

Date of next meeting: 03/03/2016

Location of next meeting: Avonmouth House, London